References
- Chaffman M, Brodgren R N, Heel R C, Speight T M, Avery G S. Auranofin: A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis. Drugs 1984; 27: 378–424
- Crooke S T, Snyder R M, Butt T R, et al. Cellular and molecular pharmacology of auranofin and related gold complexes. Biochem Pharmacol 1986; 35: 3423–31
- Hafstrom L, Seligmann B E, Freidman M M, Gallin J I. Auranofin effects early events in human polymorphonuclear neutrophil activation by receptor-mediated stimuli. J Immunol 1984; 132: 2007–14
- Froscio M, Solanki V, Hurst N P, Murray A W. Auranofin enhances phosphorylation of putative substrates of protein kinase C in human platelets. Biochem Pharmacol 1988; 37: 366–8
- Froscio M, Murray A W, Hurst N P. Inhibition of epidermal growth factor binding to HeLa cells by auranofin. Biochem Pharmacol 1987; 36: 769–72
- Downward J, Waterfield M D, Parker P J. Autophosphorylation and protein kinase C phosphorylation of the Epidermal Growth Factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J Biol Chem 1985; 260: 14538–46
- Savage R C, Jr, Cohen S. Epidermal Growth Factor and a new derivative. Rapid isolation procedures and biological and chemical characterization. J. Biol. Chem. 1972; 247: 7609–11
- Pruss R M, Herschman H R. Variants of 3T3 cells lacking mitogenic response to Epidermal Growth Factor. Proc Natl Acad Sci USA 1977; 74: 3918–21
- Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5
- Fabricant R N, De Larco J E, Todaro G J. Nerve Growth Factor receptors on human melanoma cells in culture. Proc Natl Acad Sci USA 1977; 74: 565–9
- Davis R J, Ganong B R, Bell R M, Czech M P. sn-l,2-Dioctanoylglycerol: A cell-permeable diacyl-glycerol that mimics phorbol diester action on the Epidermal Growth Factor receptor and mitogenesis. J Biol Chem 1985; 260: 1562–6
- Waterfield M D, Parker P, Mayes E. Anti-Epidermal Growth Factor receptor monoclonal antibodies. Cell Biol Int Rep 1983; 7: 535–6
- Davis R J, Czech M P. Tumor-promoting phorbol diesters cause the phosphorylation of Epidermal Growth Factor receptors in normal human fibroblasts at threonine-654. Proc Natl Acad Sci USA 1985; 82: 1974–8
- Snyder R M, Mirabelli C K, Clark M A, Ziegler J T, CroOke S T. Effect of auranofin and other gold complexes on the activities of phospholipase C. Mol Pharmacol 1987; 32: 437–42
- Parente J E, Davis P, Wong K. Gold compounds alter the distribution of protein kinase C activity in human neutrophils. Inflammation 1987; 11: 381–8
- Zalewski P D, Forbes I J, Valente L, Hurst N P. Auranofin increases the affinity of phorbol dibutyrate receptors in chronic lymphocytic leukemia cells (B cells). J Immunol 1987; 138: 3005–9
- Parker P, Coussens L, Totty N, et al. The complete primary structure of protein kinase C–the major phorbol ester receptor. Science 1986; 233: 853–9
- Hurst N P, Bell A L, Nuki G. Studies on the effect of D-penicillamine and sodium aurothiomalate therapy on superoxide anion production by monocytes from patients with rheumatoid arthritis: evidence for in vivo stimulation of monocytes. Ann Rheum Dis 1986; 45: 37–43
- Percy J S, Davis P, Russell A S, Brisson E. A longitudinal study of in vitro tests for lymphocyte function in rheumatoid arthritis. Ann Rheum Dis 1978; 37: 416–20